If you have been reading about clinical endpoint and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
The lambda particle is a type of subatomic particle in subatomic particle physics. Lambda is the set of logical axioms in the axiomatic method of logical deduction in first-order logic. Uppercase Lambda is often used as a stylized form of uppercase A, especially in science fiction. There is a poetical allusion to the use of Lambda as a shield blazon by the Spartans. Lambda is the von Mangoldt function in mathematical number theory. Lambda denotes the de Bruijn–Newman constant which is closely connected with Riemann's hypothesis. In statistics, lambda is used for the likelihood ratio. In statistics, Wilks's lambda is used in multivariate analysis of variance (MANOVA analysis) to compare group means on a combination of dependent variables. In the spectral decomposition of matrices, lambda indicates the diagonal matrix of the eigenvalues of the matrix. In computer science, lambda is the time window over which a process is observed for determining the working memory set for a digital computer's virtual memory management. In astrophysics, lambda represents the likelihood that a small body will encounter a planet or a dwarf planet leading to a deflection of a significant magnitude. An object with a large value of lambda is expected to have cleared its neighbourhood, satisfying the current definition of a planet. In crystal optics, lambda is used to represent a lattice period. In electrochemistry, lambda denotes the "equivalent conductance" of an electrolyte solution.
Caelus, the sky god, spreading the tent of the sky Aurora and Luna the personification of the subjected peoples the goddess Diana the earth goddess Ceres/Tellus—similarly represented on the Ara Pacis Apollo, Augustus's patron the personification of the tributary peoples the sun god Sol a Sphinx on each shoulder, representing the defeat of Cleopatra by Augustus The cuirass is not solely frontal; there is a backside to the armor as well. On the bottom right side of the back of the cuirass, there is a helmeted trophy with a wing above, a carnyx on the left hip, and greaves against a tree trunk. There was an iron peg that is thought to have connected the statue to a wall. This is likely due to the back being unfinished None of these interpretations are undisputed. The gods, however, probably all symbolize the continuity and logical consistency of the events—just as the sun and moon forever rise, so Roman successes are certain and divinely sanctioned. Furthermore, these successes are connected with the wearer of this breastplate, Augustus. The only active person is the Parthian king, implying that everything else is divinely desired and ordained.
=== Coolant additive === Graphene's high thermal conductivity suggests that it could be used as an additive in coolants. Preliminary research work showed that 5% graphene by volume can enhance the thermal conductivity of a base fluid by 86%. Another application due to graphene's enhanced thermal conductivity was found in PCR.
== Receptors == The studies cited above lead to the eventual cloning of the human Formyl peptide receptor 1, a G protein coupled receptor that binds fMLF and other formylated oligopeptides to mediate their stimulatory actions on human and rabbit neutrophils. Subsequently, Formyl peptide receptor 2 and Formyl peptide receptor 3 were also cloned based on the similarities in their amino acid sequence to that of formyl peptide receptor 1. Formyl peptide receptors 2 and 3 have very different abilities to bind and respond to formylated oligopeptides including fMLF compared to formyl peptide receptor 1 and compared to each other and have very different functions than those of formyl peptide receptor 1.
All committees have an allotted budget to which they must adhere. Any committee may start a project. If a project's spending becomes too much for a committee to continue funding, it must take the issue to the Project Committee. The project committee either increases the budget or decides on an external funding plan. The Bureau and Executive Committee oversee operations of the other committees.
Sources: en.wikipedia.org
However, Watson and Crick found fault in her steadfast assertion that, according to her data, a helical structure was not the only possible shape for DNA—so they had a dilemma. In an effort to clarify this issue, Max Ferdinand Perutz later published what had been in the progress report, and suggested that nothing was in the report that Franklin herself had not said in her talk (attended by Watson) in late 1951. Perutz explained that the report was to a Medical Research Council (MRC) committee that had been created to "establish contact between the different groups of people working for the Council". Randall's and Perutz's laboratories were both funded by the MRC. It is also not clear how important Franklin's unpublished results from the progress report actually were for the model-building done by Watson and Crick. After the first crude X-ray diffraction images of DNA were collected in the 1930s, William Astbury had talked about stacks of nucleotides spaced at 3.4 angström (0.34 nanometre) intervals in DNA. A citation to Astbury's earlier X-ray diffraction work was one of only eight references in Franklin's first paper on DNA. Analysis of Astbury's published DNA results and the better X-ray diffraction images collected by Wilkins and Franklin revealed the helical nature of DNA. It was possible to predict the number of bases stacked within a single turn of the DNA helix (10 per turn; a full turn of the helix is 27 angströms [2.7 nm] in the compact A form, 34 angströms [3.4 nm] in the wetter B form).
== History == Planet Half-Life ran from April 27, 1999 to August 13, 2012. Since then, it had undergone numerous format changes, both in content and aesthetic. The following is a timeline of major changes and other events.
However, although the notion of obesity as a state of 'leptin resistance' has become ingrained in the minds of many researchers, data does not directly support this contention. For example, the work of Rudolph Leibel at Columbia University shows that, in both obese and lean individuals, leptin injections do not reduce body mass. The finding that both lean and obese subjects have a similar lack of response underscores the notion that the brain is not designed to respond to increased leptin by decreasing food intake; rather, lack of leptin acts as a signal to increase food intake. Indeed, Leibel's work has shown that the decreases in serum leptin that occur post-weight-loss constitute a state of leptin deficiency, which drives increased appetite with weight loss. As such, leptin injections in weight-reduced patients can prevent increases in appetite and thereby allow patients to maintain weight loss. These studies, therefore, demonstrate that leptin treatment may be a useful strategy to treat obesity in humans, if not by driving weight loss directly then by allowing weight loss (as a result of diet and exercise) to be more readily maintained. Moreover, as geneticists learn more from the few cases of leptin gene mutations, the possibility remains that, although leptin was ineffective at treating obesity across the population, some individual obese patients might still benefit from its use as an anti-obesity medication. Research into the adipose-derived hormones adiponectin and resistin is ongoing. Like leptin, these hormones also affect energy balance and metabolism.
=== Pharmacological regulation === In certain conditions such as in the case of cardiac disease, the Na+/K+-ATPase may need to be inhibited via pharmacological means. A commonly used inhibitor used in the treatment of cardiac disease is digoxin (a cardiac glycoside) which essentially binds "to the extracellular part of enzyme i.e. that binds potassium, when it is in a phosphorylated state, to transfer potassium inside the cell" After this essential binding occurs, a dephosphorylation of the alpha subunit occurs which reduces the effect of cardiac disease. It is via the inhibiting of the Na+/K+-ATPase that sodium levels will begin to increase within the cell which ultimately increases the concentration of intracellular calcium via the sodium-calcium exchanger. This increased presence of calcium is what allows for the force of contraction to be increased. In the case of patients where the heart is not pumping hard enough to provide what is needed for the body, use of digoxin helps to temporarily overcome this.
Sources: en.wikipedia.org
== Signs and symptoms == Symptoms of beriberi include weight loss, emotional disturbances, impaired sensory perception, weakness and pain in the limbs, and periods of irregular heart rate. Edema (swelling of bodily tissues) is common. It may increase the amount of lactic acid and pyruvic acid within the blood. In advanced cases, the disease may cause high-output cardiac failure and death. Symptoms may occur concurrently with those of Wernicke's encephalopathy, a primarily neurological thiamine deficiency-related condition. Beriberi is divided into four categories. The first three are historical and the fourth, gastrointestinal beriberi, was recognized in 2004:
Maapliv is a medication used to treat an acute decompensation episode (sudden worsening) of maple syrup urine disease. Maple syrup urine disease is an inherited disorder in which the body is unable to break down certain building blocks of protein known as branched-chain amino acids, including leucine, isoleucine and valine. As a result, these amino acids build up in the body, including in the brain, where leucine in particular can lead to brain damage. Maapliv is for use in people who cannot receive BCAA-free amino acids by mouth or via a feeding tube. Maapliv contains the amino acids L-alanine, L-arginine, L-aspartic acid, L-cysteine hydrochloride monodhydrate, L-glutamic acid, glycine, L-histidine, L-lysine, L-methionine, L-phenylalanine, L-proline, L-serine, taurine, L-threonine, L-tryptophan, and L-tyrosine. Maapliv is indicated for the treatment of maple syrup urine disease presenting with an acute decompensation episode in people from birth who are not eligible for an oral and enteral branched- chain amino acids free (BCAA- free) formulation. Maapliv was authorized for medical use in the European Union in July 2025.
2026 United States federal budget – $6.8 trillion (submitted 2025 by President Trump) 2025 United States federal budget – $7 trillion (submitted 2024 by President Biden) 2024 United States federal budget – $6.8 trillion (submitted 2023 by President Biden) 2023 United States federal budget – $6.1 trillion (submitted 2022 by President Biden) 2022 United States federal budget – $6.3 trillion (submitted 2021 by President Biden) 2021 United States federal budget – $6.8 trillion (submitted 2020 by President Trump) 2020 United States federal budget – $6.5 trillion (submitted 2019 by President Trump) 2019 United States federal budget – $4.4 trillion (submitted 2018 by President Trump) 2018 United States federal budget – $4.1 trillion (submitted 2017 by President Trump) 2017 United States federal budget – $4.2 trillion (submitted 2016 by President Obama) 2016 United States federal budget – $4 trillion (submitted 2015 by President Obama) 2015 United States federal budget – $3.9 trillion (submitted 2014 by President Obama) 2014 United States federal budget – $3.5 trillion (submitted 2013 by President Obama) 2013 United States federal budget – $3.8 trillion (submitted 2012 by President Obama) 2012 United States federal budget – $3.7 trillion (submitted 2011 by President Obama) 2011 United States federal budget – $3.8 trillion (submitted 2010 by President Obama) 2010 United States federal budget – $3.6 trillion (submitted 2009 by President Obama) 2009 United States federal budget – $3.5 trillion (submitted 2008 by President Bush) 2008 United States federal budget – $2.9 trillion (submitted 2007 by President Bush) 2007 United States federal budget – $2.8 trillion (submitted 2006 by President Bush) 2006 United States federal budget – $2.7 trillion (submitted 2005 by President Bush) 2005 United States federal budget – $2.4 trillion (submitted 2004 by President Bush) 2004 United States federal budget – $2.3 trillion (submitted 2003 by President Bush) 2003 United States federal budget – $2.2 trillion (submitted 2002 by President Bush) 2002 United States federal budget – $2 trillion (submitted 2001 by President Bush) 2001 United States federal budget – $1.9 trillion (submitted 2000 by President Clinton) 2000 United States federal budget – $1.8 trillion (submitted 1999 by President Clinton) 1999 United States federal budget – $1.7 trillion (submitted 1998 by President Clinton) 1998 United States federal budget – $1.7 trillion (submitted 1997 by President Clinton) 1997 United States federal budget – $1.6 trillion (submitted 1996 by President Clinton) 1996 United States federal budget – $1.6 trillion (submitted 1995 by President Clinton) The budget year runs from October 1 to September 30 the following year and is submitted by the President to Congress prior to October for the following year. In this way the budget of 2013 is submitted before the end of September 2012. This means that the budget of 2001 was submitted by Bill Clinton and was in force during most of George W. Bush's first year in office. The budget submitted by George W. Bush in his last year in office was the budget of 2009, which was in force through most of Barack Obama's first year in office. The President's budget also contains revenue and spending projections for the current fiscal year, the coming fiscal years, as well as several future fiscal years. In recent years, the President's budget contained projections five years into the future. The Congressional Budget Office (CBO) issues a "Budget and Economic Outlook" each January and an analysis of the President's budget each March. CBO also issues an updated budget and economic outlook in August. Actual budget data for prior years is available from the Congressional Budget Office; see the "Historical Budget Data" links on the main page of "The Budget and Economic Outlook". and from the Office of Management and Budget (OMB).
=== Molecular recognition and complexation === Molecular recognition is the specific binding of a guest molecule to a complementary host molecule to form a host–guest complex. Often, the definition of which species is the "host" and which is the "guest" is arbitrary. The molecules are able to identify each other using non-covalent interactions. Key applications of this field are the construction of molecular sensors and catalysis.
One example of how these changes have been used to study activities is the New York African Burial Ground in New York. This provides evidence of the brutal working conditions under which the enslaved labored; osteoarthritis of the vertebrae was common even among the young. The pattern of osteoarthritis combined with the early age of onset provides evidence of labor that resulted in mechanical strain to the neck. One male skeleton shows stress lesions at 37 percent of 33 muscle or ligament attachments, showing he experienced significant musculoskeletal stress. Overall, the interred show signs of significant musculoskeletal stress and heavy workloads, although workload and activities varied by individual. Some show high levels of stress, while others do not. This indicates the variety of types of labor (e.g., domestic vs. carrying heavy loads).
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.